153 related articles for article (PubMed ID: 35320889)
21. The efficacy of systematic lymph node dissection in advanced epithelial ovarian cancer during interval debulking surgery performed after neoadjuvant chemotherapy.
Eoh KJ; Yoon JW; Lee I; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
J Surg Oncol; 2017 Sep; 116(3):329-336. PubMed ID: 28542980
[TBL] [Abstract][Full Text] [Related]
22. Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer.
Chambers LM; Kuznicki M; Yao M; Chichura A; Gruner M; Reizes O; Debernardo R; Rose PG; Michener C; Vargas R
Gynecol Oncol; 2020 Dec; 159(3):699-705. PubMed ID: 32950250
[TBL] [Abstract][Full Text] [Related]
23. External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma.
Lee JY; Chung YS; Na K; Kim HM; Park CK; Nam EJ; Kim S; Kim SW; Kim YT; Kim HS
J Gynecol Oncol; 2017 Nov; 28(6):e73. PubMed ID: 28758379
[TBL] [Abstract][Full Text] [Related]
24. Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology Group study.
Ayhan A; Ozkan NT; Sarı ME; Celik H; Dede M; Akbayır Ö; Güngördük K; Şahin H; Haberal A; Güngör T; Arvas M; Meydanlı MM
J Gynecol Oncol; 2018 Jan; 29(1):e12. PubMed ID: 29185270
[TBL] [Abstract][Full Text] [Related]
25. Risks and benefits of systematic lymphadenectomy during interval debulking surgery for advanced high grade serous ovarian cancer.
Benoit L; Koual M; Le Frère-Belda MA; Zerbib J; Fournier L; Nguyen-Xuan HT; Delanoy N; Bentivegna E; Bats AS; Azaïs H
Eur J Surg Oncol; 2022 Jan; 48(1):275-282. PubMed ID: 34753619
[TBL] [Abstract][Full Text] [Related]
26. Effects of pretreatment radiological and pathological lymph node statuses on prognosis in patients with ovarian cancer who underwent interval debulking surgery with lymphadenectomy following neoadjuvant chemotherapy.
Komatsu H; Iida Y; Osaku D; Shimogai R; Chikumi J; Sato S; Oishi T; Harada T
J Obstet Gynaecol Res; 2021 Jan; 47(1):152-158. PubMed ID: 32830400
[TBL] [Abstract][Full Text] [Related]
27. Impact of no residual disease on postoperative computed tomography on survival in patients with optimally debulked advanced high-grade serous ovarian cancer during upfront surgery.
Lim H; In Shim J; Park SJ; Noh J; Kim TM; Lee M; Choi CH; Chung HH; Kim TJ; Lee JW; Kim JW; Kim BG; Park NH; Song YS; Kim SY; Park SY; Kim HS; Lee YY
Gynecol Oncol; 2022 Jun; 165(3):493-499. PubMed ID: 35367074
[TBL] [Abstract][Full Text] [Related]
28. Comparison of stage III mucinous and serous ovarian cancer: a case-control study.
Firat Cuylan Z; Karabuk E; Oz M; Turan AT; Meydanli MM; Taskin S; Sari ME; Sahin H; Ulukent SC; Akbayir O; Gungorduk K; Gungor T; Kose MF; Ayhan A
J Ovarian Res; 2018 Oct; 11(1):91. PubMed ID: 30376858
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy.
Cuylan ZF; Meydanli MM; Sari ME; Akbayir O; Celik H; Dede M; Sahin H; Gungorduk K; Kuscu E; Ozgul N; Gungor T; Ayhan A
J Obstet Gynaecol Res; 2018 Jul; 44(7):1284-1293. PubMed ID: 29727055
[TBL] [Abstract][Full Text] [Related]
30. Cardiophrenic lymph node resection in cytoreduction for primary advanced or recurrent epithelial ovarian carcinoma: a cohort study.
Lopes A; Rangel Costa RL; di Paula R; Anton C; Calheiros Y; Sartorelli V; Kanashiro YM; de Lima JA; Yamada A; Pinto GLS; Vianna MR; Nogueira Dias Genta ML; Ribeiro U; Dos Santos MO
Int J Gynecol Cancer; 2019 Jan; 29(1):188-194. PubMed ID: 30640703
[TBL] [Abstract][Full Text] [Related]
31. Fully sialylated alpha-chain of complement 4-binding protein (A2160): a novel prognostic marker for epithelial ovarian carcinoma.
Matsuo K; Tanabe K; Ikeda M; Shibata T; Kajiwara H; Miyazawa M; Miyazawa M; Hayashi M; Shida M; Hirasawa T; Roman LD; Mikami M
Arch Gynecol Obstet; 2018 Mar; 297(3):749-756. PubMed ID: 29340789
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by interval debulking surgery: A multicenter cohort analysis from the FRANCOGYN study group.
Vincent L; Jankowski C; Ouldamer L; Ballester M; Bendifallah S; Bolze PA; Akladios C; Costaz H; Lavoué V; Canlorbe G; Collinet P; Touboul C; Huchon C; Bricou A; Dridi S; Padéano MM; Bengrine L; Arnould L; Coutant C;
Eur J Surg Oncol; 2020 Sep; 46(9):1689-1696. PubMed ID: 32417154
[TBL] [Abstract][Full Text] [Related]
33. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
[TBL] [Abstract][Full Text] [Related]
34. The detrimental effect of adopting interval debulking surgery in advanced stage low-grade serous ovarian cancer.
Bogani G; Leone Roberti Maggiore U; Paolini B; Diito A; Martinelli F; Lorusso D; Raspagliesi F
J Gynecol Oncol; 2019 Jan; 30(1):e4. PubMed ID: 30479088
[TBL] [Abstract][Full Text] [Related]
35. Impact of lymphadenectomy on survival after recurrence in patients with advanced ovarian cancer without suspected lymph node metastasis.
Paik ES; Shim M; Choi HJ; Lee YY; Kim TJ; Lee JW; Kim BG; Bae DS; Choi CH
Gynecol Oncol; 2016 Nov; 143(2):252-257. PubMed ID: 27567053
[TBL] [Abstract][Full Text] [Related]
36. The role of lymphadenectomy in patients with stage III&IV uterine serous carcinoma: Results of multicentric Turkish study.
Cakir C; Kilic F; Kilic C; Tokgozoglu N; Ersak B; Ayhan S; Akar S; Yuksel D; Korkmaz V; Boran N; Toptas T; Kimyon Comert G; Ureyen I; Tasci T; Turkmen O; Moraloglu Tekin O; Ustun Y; Turan T
J Gynecol Obstet Hum Reprod; 2021 May; 50(5):102063. PubMed ID: 33453448
[TBL] [Abstract][Full Text] [Related]
37. Stage, treatment and survival of low-grade serous ovarian carcinoma in the Netherlands: A nationwide study.
De Decker K; Wenzel HHB; Bart J; van der Aa MA; Kruitwagen RFPM; Nijman HW; Kruse AJ
Acta Obstet Gynecol Scand; 2023 Mar; 102(3):246-256. PubMed ID: 36734363
[TBL] [Abstract][Full Text] [Related]
38. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
Bian C; Yao K; Li L; Yi T; Zhao X
Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
[TBL] [Abstract][Full Text] [Related]
39. Incidence and prognostic significance of inguinal lymph node metastasis in women with newly diagnosed epithelial ovarian cancer.
Chalif J; Yao M; Gruner M; Kuznicki M; Vargas R; Rose PG; Michener C; DeBernardo R; Chambers L
Gynecol Oncol; 2022 Apr; 165(1):90-96. PubMed ID: 35272875
[TBL] [Abstract][Full Text] [Related]
40. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.
Zhang J; Liu N; Zhang A; Bao X
J Obstet Gynaecol Res; 2018 Sep; 44(9):1808-1816. PubMed ID: 30019801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]